Establishment and Characterization of a Stable Producer Cell Line Generation Platform for the Manufacturing of Clinical-Grade Lentiviral Vectors.

To date, nearly 300 lentiviral-based gene therapy clinical trials have been conducted, with eight therapies receiving regulatory approval for commercialization. These advances, along with the increased number of advanced-phase clinical trials, have prompted contract development and manufacturing organizations (CDMOs) to develop innovative strategies to address the growing demand for large-scale batches of lentiviral vectors (LVVs). Consequently, manufacturers have focused on optimizing processes under good manufacturing practices (GMPs) to improve cost-efficiency, increase process robustness, and ensure regulatory compliance.

Transcriptome characteristics of filamentous fungi deduced using high-throughput analytical technologies.

Transcriptomes are the complete set of genome sequences transcribed at a given time point by a given organism, organ, tissue or cell. The availability of high-throughput analytical techniques and, especially, the democratization of the use of RNA sequencing using new platforms have made it possible to transform transcriptome analysis into a common study affordable by most laboratories. In many cases, however, there is a certain level of prevention toward the use of these technologies because of the lack of knowledge about what has been done, what can be done and how high-throughput sequencing can help us solve specific scientific questions.